Silvia Taylor of Novavax discusses how new vaccine technologies are reducing side effects, lowering costs, and enhancing immune response.
Silvia Taylor
Advertisement
Silvia Taylor is EVP of corporate affairs and head of Novavax Sweden for Novavax.
Articles by Silvia Taylor
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
How Basket-Trials are Reshaping Drug Development Timelines
2
Accelerating Speed to Patient: A Conversation With Eli Lilly’s Sarah O’Keeffe
3
Parabilis Reaches $3.7 Billion Market Cap on Frist Day Listed on NASDAQ
4
China Pharma Trends: Premium Pricing and Priority Access for True Innovations
5